Lonza and Bioqube sign biologics agreement

Article

Five-year deal covers manufacturing of molecules, ranging from monoclonal antibodies to antibody-drug conjugates

Bioqube Ventures, a European venture capital firm, and Lonza, a contract development and manufacturing organization serving the pharma, biotech and nutrition sectors, announced a five-year framework agreement that features a strategic collaboration for the development and manufacturing of biologics and small molecules.

The agreement was designed to support the needs of the venture capital firm and its portfolio companies looking to simplify their molecule development. Per the deal’s terms, Lonza will be supporting Bioqube throughout the due diligence of candidate biotechs, while also offering both advice and services to its portfolio clients.

The partnership leverages Lonza's knowledge and technology that speeds up timelines, while lowering risks of the development and manufacturing of molecules ranging from monoclonal antibodies, complex proteins, and small molecules to antibody-drug conjugates. According to the involved parties, the holistic approach to drug substance and drug product development, and manufacturing across multiple platforms simplifies the supply chain, decreases process complexity, and allows for shortened development timelines.

“…The cornerstone of our ability to successfully accelerate development programs and commercialize products is our proven track record, comprehensive resources and the global network that we bring to our customer's portfolio companies,” says Pnina Weitz, Lonza’s global head of venture capital business development & relationship management.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.